HIV prevention cost-effectiveness: a systematic review

Galárraga, Omar; Colchero, M. Arantxa; Wamai, Richard G.; Bertozzi, Stefano M.
January 2009
BMC Public Health;2009 Supplement 1, Vol. 9, Special section p1
Academic Journal
Background: After more than 25 years, public health programs have not been able to sufficiently reduce the number of new HIV infections. Over 7,000 people become infected with HIV every day. Lack of convincing evidence of cost-effectiveness (CE) may be one of the reasons why implementation of effective programs is not occurring at sufficient scale. This paper identifies, summarizes and critiques the CE literature related to HIV-prevention interventions in low- and middle-income countries during 2005-2008. Methods: Systematic identification of publications was conducted through several methods: electronic databases, internet search of international organizations and major funding/implementing agencies, and journal browsing. Inclusion criteria included: HIV prevention intervention, year for publication (2005-2008), setting (low- and middle-income countries), and CE estimation (empirical or modeling) using outcomes in terms of cost per HIV infection averted and/or cost per disability-adjusted life year (DALY) or quality-adjusted life year (QALY). Results: We found 21 distinct studies analyzing the CE of HIV-prevention interventions published in the past four years (2005-2008). Seventeen CE studies analyzed biomedical interventions; only a few dealt with behavioral and environmental/structural interventions. Sixteen studies focused on sub-Saharan Africa, and only a handful on Asia, Latin America and Eastern Europe. Many HIV-prevention interventions are very cost effective in absolute terms (using costs per DALY averted), and also in country-specific relative terms (in cost per DALY measured as percentage of GDP per capita). Conclusion: There are several types of interventions for which CE studies are still not available or insufficient, including surveillance, abstinence, school-based education, universal precautions, prevention for positives and most structural interventions. The sparse CE evidence available is not easily comparable; thus, not very useful for decision making. More than 25 years into the AIDS epidemic and billions of dollars of spending later, there is still much work to be done both on costs and effectiveness to adequately inform HIV prevention planning.


Related Articles

  • Achieving Allocative Efficiency in Healthcare: Nice in Theory, not so NICE in Practice? Paulden, Mike; McCabe, Christopher; Karnon, Jonathan // PharmacoEconomics;Apr2014, Vol. 32 Issue 4, p315 

    The authors reflect on the article by S. Eckermann and B. Pekarsky which challenges several concepts including the methods of determining cost-effectiveness threshold for assessing the potential health technology in public healthcare system. They discuss the National Institute forHealth and Care...

  • The value of the $50 000 per QALY threshold.  // PharmacoEconomics & Outcomes News;Sep2014, Vol. 711 Issue 1, p9 

    The article reflects on the value of the $50,000 per quality-adjusted life year (QALY) threshold in the U.S. for assessing the cost-effectiveness of an intervention.

  • Is expanding HPV vaccination programs to include school-aged boys likely to be value-for-money: a cost-utility analysis in a country with an existing school-girl program. Pearson, Amber L.; Kvizhinadze, Giorgi; Wilson, Nick; Smith, Megan; Canfell, Karen; Blakely, Tony // BMC Infectious Diseases;2014, Vol. 14 Issue 1, p1 

    Background Similar to many developed countries, vaccination against human papillomavirus (HPV) is provided only to girls in New Zealand and coverage is relatively low (47% in school-aged girls for dose 3). Some jurisdictions have already extended HPV vaccination to school-aged boys. Thus,...

  • Cost–utility analysis of telemonitoring versus conventional hospital-based follow-up of patients with pacemakers. The NORDLAND randomized clinical trial. Lopez-Villegas, Antonio; Catalan-Matamoros, Daniel; Peiro, Salvador; Lappegard, Knut Tore; Lopez-Liria, Remedios // PLoS ONE;1/29/2020, Vol. 15 Issue 1, p1 

    Introduction: The aim of our study was to perform an economic assessment in order to check whether or not telemonitoring of users with pacemakers offers a cost-effective alternative to traditional follow-up in outpatient clinics. Methods: We used effectiveness and cost data from the NORDLAND...

  • The Cost-Effectiveness of Low-Cost Essential Antihypertensive Medicines for Hypertension Control in China: A Modelling Study. Gu, Dongfeng; He, Jiang; Coxson, Pamela G.; Rasmussen, Petra W.; Huang, Chen; Thanataveerat, Anusorn; Tzong, Keane Y.; Xiong, Juyang; Wang, Miao; Zhao, Dong; Goldman, Lee; Moran, Andrew E. // PLoS Medicine;8/4/2015, Vol. 12 Issue 8, p1 

    Background: Hypertension is China’s leading cardiovascular disease risk factor. Improved hypertension control in China would result in result in enormous health gains in the world’s largest population. A computer simulation model projected the cost-effectiveness of hypertension...

  • Mini Review of the Cost-Effectiveness of Unilateral Osseointegrated Implants in Adults: Possibly Cost-Effective for the Correct Indication. Crowson, Matthew G.; Tucci, Debara L. // Audiology & Neuro-Otology;Apr2016, Vol. 21 Issue 2, p69 

    An osseointegrated implant (e.g. bone-anchored hearing aid, BAHA) is a surgically implantable device for unilateral sensorineural and unilateral or bilateral conductive hearing loss in patients who otherwise cannot use or do not prefer a conventional air conduction hearing aid (ACHA). The...

  • Computer-Aided Instruction Program for BIOSIS Previews.  // Information Today;Jun1993, Vol. 10 Issue 6, p13 

    The article reports that BIOSIS has released a diskette version of the Basic Training Course for its biological and medical database, BIOSIS Previews. This computer-aided assistance program, entitled Discovering BIOSIS Previews: An Interactive Disk, is a comprehensive, cost-effective and...

  • On the welfare theoretic foundation of CEA: comment. Breyer, Friedrich // European Journal of Health Economics;Dec2010, Vol. 11 Issue 6, p595 

    This is a comment on a recent paper by Bengt Liljas (Eur J Health Econ 11:5-13, 2010) in this Journal. The author's analysis is flawed because he fails to take the envelope theorem into account. As a bottom line, we conclude that from a welfare theoretic point of view, future consumption and...

  • Determining risk preferences for pain. Kroll, Eike B.; Trarbach, Judith N.; Vogt, Bodo // NeuroPsychoEconomics Conference Proceedings;2011, p25 

    The QALY concept is the commonly used approach in research to evaluate the efficiency of therapies in cost utility analysis. We investigate the risk neutrality assumption for time of the QALY concept: can time be included as a linear factor? Various studies show that this assumption does not...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics